Rapid Dose Therapeutics Corp. provides the following update regarding the signing of a number of strategically significant agreements with Oakland Health Limited to support and accelerate the development and commercialization of the Company's QuickStrip system for COVID-19 vaccines. The Summit brought together world leaders from governments, international agencies, science and academia, industry, philanthropy, and civil society to continue the valuable work being done to meet global unmet medical needs and mobilize the critical resources required for CEPI's $3.5 billion pandemic plan to ensure a more equitable response to future pandemics.Ms. Thiel's standing within these important groups has provided the Company with an opportunity to develop global awareness of RDT's needle-free vaccine platform as a viable solution consistent with the mandate of the 100 Days Mission. Details of the Agreements: The agreements (i) crystallize the carefully crafted relationship between RDT and RD Therapeutics and its principals through a Shareholders' Agreement which grants RD Therapeutics a 5% interest in RDT's newly created wholly-owned subsidiary, Rapid Dose Therapeutics (UK) Ltd. UK Co will be granted the exclusive worldwide license to sell products derived from the Intellectual Property behind the QuickStripVax and (ii) set out, through Collaboration and Services Agreements, the responsibilities of RD Therapeutics to maximize and accelerate the Development of the
QuickStripVax leading to commercialization. In consideration of the obligations created in these agreements, RDT has granted a Royalty to RD Therapeutics in the amount of 2.5% of the net selling price derived from the sales generated from the licensing arrangement discussed. About Rapid Dose Therapeutics Corp. Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation.